EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Intratumoral heterogeneity of cancer driver genomic alterations in myxoid liposarcomas

Adrian Schmid iD, Anja E Eisenhardt, Balazs Bogner iD, Alexander Runkel iD, Ute Lausch, Thomas Pauli, Laura N Antolini, Anika Boneberg, Jurij Kiefer, Peter Bronsert, Melanie Boerries, Steffen U Eisenhardt und 1 weitere

Cancer · 2025

DOI: 10.1002/cncr.35937 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2025. Verfasst von Adrian Schmid und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Plastic and Hand Surgery, Medical Center - University of Freiburg, Freiburg im Breisgau, Germany. Hauptthemen laut MEDLINE: Liposarcoma, Myxoid, Telomerase. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Berta-Ottenstein-Programme for Advanced Clinician Scientists, Dres. Bayer Stiftung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Myxoid liposarcomas (MLS) are rare malignant mesenchymal tumors characterized by specific translocations t(12;16) and t(12;22) with limited additional driver mutations, most notably in PIK3CA and the TERT promoter. PIK3CA is considered a promising therapeutic target. However, effective treatments require the uniform presence of mutation throughout the tumor. Therefore, this study evaluated intratumoral heterogeneity of driver mutations in MLS.

Methods

In total, 170 samples from 20 tumors (12 patients) were analyzed using an MLS‐specific next‐generation sequencing (NGS) panel. This included detecting the t(12;16) and t(12;22) translocations and known driver mutations.

Results

Patient‐specific t(12;16) or t(12;22) translocations were detected in all 20 tumors (159 of 170 samples; 94%) and remained identical in primary tumors, recurrences, and metastases. TERT promoter mutations were identified in 17 of 20 tumors (85%) and were distributed similarly across samples. In contrast, PIK3CA mutations were present in only 66 of 170 samples (39%), with these and the remaining driver mutations localized only in subclones within individual tumors.

Conclusions

Therapies that target PIK3CA are unlikely to succeed because of its limited subclonal distribution. In contrast, the ubiquitous presence of t(12;16), t(12;22), and TERT promoter mutations across MLS tumors suggests that these are more effective therapeutic targets for future treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liposarcoma, MyxoidTelomeraseHumansClass I Phosphatidylinositol 3-KinasesFemaleMaleMutationMiddle AgedAgedAdultPromoter Regions, GeneticTranslocation, GeneticHigh-Throughput Nucleotide SequencingGenetic HeterogeneityAged, 80 and over

Stichwörter der Autor:innen

clonal evolutionmyxoid liposarcomanext‐generation sequencingsoft tissue sarcomatumor heterogeneity

Substanzen

Class I Phosphatidylinositol 3-KinasesPIK3CA protein, humanTelomeraseTERT protein, human

Autor:innen und Institutionen

  • Department of Plastic and Hand Surgery, Medical Center - University of Freiburg, Freiburg im Breisgau, Germany.
  • Department of Radiology, Medical Center - University of Freiburg, Freiburg im Breisgau, Germany.
  • Institute of Medical Bioinformatics and Systems Medicine, Medical Center - University of Freiburg, Freiburg im Breisgau, Germany.
  • Institute for Surgical Pathology, Medical Center - University of Freiburg, Freiburg im Breisgau, Germany.
  • Tumorbank Comprehensive Cancer Center Freiburg, Medical Center - University of Freiburg, Freiburg im Breisgau, Germany.

ORCID-Profile: Adrian Schmid, Balazs Bogner, Alexander Runkel

Förderung

  • Deutsche Forschungsgemeinschaft
  • Berta-Ottenstein-Programme for Advanced Clinician Scientists
  • Dres. Bayer Stiftung
  • Berta-Ottenstein-Programme for Clinician Scientists

Zitieren

APA

Schmid, A., Eisenhardt, A. E., Bogner, B., Runkel, A., Lausch, U., Pauli, T., Antolini, L. N., Boneberg, A., Kiefer, J., Bronsert, P., Boerries, M., Eisenhardt, S. U., & Braig, D. (2025). Intratumoral heterogeneity of cancer driver genomic alterations in myxoid liposarcomas. Cancer. https://doi.org/10.1002/cncr.35937

Vancouver

Schmid A, Eisenhardt AE, Bogner B, Runkel A, Lausch U, Pauli T, et al. Intratumoral heterogeneity of cancer driver genomic alterations in myxoid liposarcomas. Cancer. 2025. doi:10.1002/cncr.35937

BibTeX
@article{Schmid2025,
  author = {Schmid, Adrian and Eisenhardt, Anja E and Bogner, Balazs and Runkel, Alexander and Lausch, Ute and Pauli, Thomas and Antolini, Laura N and Boneberg, Anika and Kiefer, Jurij and Bronsert, Peter and Boerries, Melanie and Eisenhardt, Steffen U and Braig, David},
  title = {Intratumoral heterogeneity of cancer driver genomic alterations in myxoid liposarcomas},
  journal = {Cancer},
  year = {2025},
  doi = {10.1002/cncr.35937}
}
Kostenlos starten →